Enanta Pharmaceuticals, Inc.
NASDAQ:ENTABiotechnology
-$0.09 today
- Market cap
- $239.70M
- Beta
- 0.99
- P/E (TTM)
- -4.3
- EPS (TTM)
- -$2.90
Volume 0.81M
Average 0.17M
ENTA Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Enanta Pharmaceuticals, Inc.NASDAQ: ENTA
Depreciation & Amortization · Q2 FY2026 · quarter ended Mar 2026
Depreciation & amortization grows, but more slowly than its trailing trend
Q2 FY2026 depreciation & amortization of $1.21M rose 0.5% year over year, behind the +56.5% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 3.3% from the prior quarter. Over 3 fiscal years it compounded at +19.6% a year.
Context
- Depreciation & amortization amounted to 7.8% of revenue in FY2025, up 4.3 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +0.5% toward the trailing-twelve-month pace of +56.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 5.09M USD
- Year-over-year change
- +117.9%
- 4-year CAGR
- +11.2%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 5.09M | +117.9% |
| FY2024 | 2024-09-30 | 2.34M | -1.5% |
| FY2023 | 2023-09-30 | 2.37M | -20.2% |
| FY2022 | 2022-09-30 | 2.97M | -10.8% |
| FY2021 | 2021-09-30 | 3.33M | — |
Depreciation & Amortization vs competitors
How ENTA compares with its peers on the latest reported figures
- ENTA's LTM Mar 2026 depreciation & amortization of $4.95M is the 3rd largest of the 11 companies compared; the peer median is $2.98M.
- Its year-over-year change of +56.5% is the 3rd highest of 11, against a peer median of -3.6%.
- Depreciation & amortization amounts to 7.2% of revenue for ENTA, versus a peer median of 10.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $7.81M | -13.0% | +11.0% | 3469.8% | |
| LTM Mar 2026 | $6.32M | -1.1% | +23.7% | — | |
| LTM Mar 2026 | $4.95M | +56.5% | +19.6% | 7.2% | |
| LTM Mar 2026 | $4.42M | +82.7% | +85.3% | 31.9% | |
| LTM Mar 2026 | $3.61M | -20.6% | -13.1% | 9.9% | |
| LTM Mar 2026 | $3.13M | -28.6% | +0.0% | 27.9% | |
| LTM Mar 2026 | $2.84M | -8.0% | -25.0% | 10.1% | |
| LTM Mar 2026 | $1.53M | +180.4% | +0.4% | 9.2% | |
| LTM Mar 2026 | $531.13K | +15.1% | -4.3% | — | |
| LTM Mar 2026 | $416K | +0.0% | +17.0% | — | |
| LTM Mar 2026 | $122K | -6.2% | -36.3% | 0.2% | |
| Peer median (excluding ENTA) | $2.98M | -3.6% | +0.2% | 10.1% | |
Competitors are the stored peer set for ENTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Sep 2021 | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Net Income | (79M) | (121.76M) | (133.82M) | (116.05M) | (81.89M) |
| Depreciation & Amortization | 3.33M | 2.97M | 2.37M | 2.34M | 5.09M |
| Deferred Income Tax | 345K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 20.99M | 26.97M | 28.22M | 26.8M | 18.57M |
| Change in Working Capital | (13.69M) | 6.79M | 8.02M | 7.13M | 39.91M |
| Accounts Receivables | (24.3M) | 11.8M | 9.42M | 973K | 31.76M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 3.77M | (4.63M) | (1.15M) | (414K) | (1.31M) |
| Other Working Capital | 6.84M | (372K) | (243K) | 6.57M | 9.46M |
| Other Non-Cash Items | (1.98M) | 242K | (7.95M) | 1.02M | (946K) |
| Operating Cash Flow | (70M) | (84.78M) | (103.15M) | (78.76M) | (19.27M) |
| Capital Expenditures | (750K) | (2.13M) | (9.06M) | (17.95M) | (12.9M) |
| Acquisitions (Net) | (37.74M) | (54.9M) | 44.52M | 0 | 0 |
| Purchases of Investments | (307.35M) | (171.45M) | (373.39M) | (307.28M) | (209.63M) |
| Sales of Investments | 345.09M | 228.47M | 328.87M | 383.47M | 262.87M |
| Other Investing Activities | 37.74M | 54.9M | (44.52M) | 0 | 0 |
| Investing Cash Flow | 36.99M | 54.9M | (53.58M) | 58.24M | 40.35M |
| Debt Repayment | 0 | 0 | 199.68M | (27.48M) | (26.49M) |
| Common Stock Issued | 3.61M | 21.26M | 2.21M | 147K | 145K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (534K) | (1.23M) | (3.76M) | (294K) | (277K) |
| Financing Cash Flow | 3.08M | 20.03M | 198.13M | (27.63M) | (26.62M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (29.93M) | (9.85M) | 41.39M | (48.16M) | (5.54M) |
| Free Cash Flow | (70.75M) | (86.91M) | (112.21M) | (96.71M) | (32.17M) |
Enanta Pharmaceuticals, Inc.
NASDAQ:ENTA
Intrinsic Alpha fair value
Locked
Current Price
$8.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.